The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells
in participants with previously treated advanced solid tumors (prostate) expressing high
levels of prostate stem cell antigen (PSCA). Participants' T cells are modified to
recognize and target the PSCA tumor marker on cancer cells.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02744287.
The goal of this study is to characterize the feasibility, safety, and clinical activity
of PSCA-specific CAR-T cells, BPX-601, administered with rimiducid to subjects with
previously treated, PSCA-positive advanced solid tumors (prostate). BPX-601 CAR-T cells
are genetically engineered to express a chimeric antigen receptor (CAR) to target the
PSCA antigen and a rimiducid-inducible signaling domain which functions as a molecular
"go-switch" to enhance activation and proliferation.
Phase 1: Cell dose escalation to identify the maximum dose of BPX-601 administered with
single or repeat doses of rimiducid.
Phase 2: Indication-specific dose expansion to assess the safety, pharmacodynamics
(including BPX-601 persistence), and clinical activity at the recommended dose identified
in Phase 1 in various PSCA-expressing solid tumors.
Lead OrganizationBellicum Pharmaceuticals
